Cargando…
PD-1 inhibitor treatment in a penile cancer patient with MMR/MSI status heterogeneity: A case report
Penile cancer is a rare malignant disease. Paclitaxel combined with platinum is often used as a first-line chemotherapeutic regimen for late-stage penile cancer, and there is no standard second-line treatment. Clinical trials of immunotherapy for penile cancer are ongoing. There are no reports on PD...
| Autores principales: | , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Taylor & Francis
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9746458/ https://www.ncbi.nlm.nih.gov/pubmed/36162043 http://dx.doi.org/10.1080/21645515.2022.2121122 |